# Moleculin Biotech, Inc. (MBRX)

> Moleculin Biotech, Inc. (MBRX) trades at $7.74 (-2.40%) as of 7:56:24 PM EST on Nov 20, 2026, +31.41% over the past month. Market cap is $8.22M, with 1.0 days to cover in short interest.

Canonical: https://massive.com/quote/mbrx
Data as of: 2026-11-21T00:56:24.700Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$7.74** -0.19 (-2.40%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$8.16** +0.42 (+5.43%)
As of 7:56:24 PM EST on Nov 20, 2026 · After hours

## Stock performance

How Moleculin Biotech, Inc. (MBRX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -2.40% |
| 1W | -1.65% |
| 1M | +31.41% |
| YTD | -88.31% |
| 1Y | -95.77% |
| 52-wk range | $3.23 – $202.50 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for MBRX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $7.57 – $8.40 |
| Open | $8.34 |
| Prev close | $7.93 |
| Volume | 49.56K |
| Market cap | $8.22M |
| Shares out | 1.06M |

## Valuation and profitability ratios

Valuation and profitability ratios for Moleculin Biotech, Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 0.57 |
| P/FCF | — |
| ROE | -99.3% |
| ROA | -69.4% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[Moleculin Biotech, Inc. (MBRX) insider trading](https://massive.com/quote/mbrx/insider-trading.md): open-market Form 4 buys and sells by Moleculin Biotech, Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events Moleculin Biotech, Inc. has disclosed to the SEC on Form 8-K.

- Nov 18, 2026 · Patent milestone
  “On November 18, 2026, Moleculin Biotech, Inc. issued a press release which announced that South Korea's Ministry of Intellectual Property has issued a decision to grant a patent covering the Company's method of reconstituting liposomal Annamycin (also known as naxtarubicin). Korean patent application No. 10-2022-7000486 received the decision to grant patent titled, "Method of Reconstituting Liposomal Annamycin."”
- Nov 16, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 16, 2026, Moleculin Biotech, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026, and recent operational highlights.”
- Nov 12, 2026 · Patent milestone
  “On November 12, 2026, Moleculin Biotech, Inc. issued a press release which announced the grant of an Australian patent covering the preparation of preliposomal Annamycin lyophilizate, strengthening the Company's intellectual property protection for a key aspect of Annamycin's formulation technology. Australian Patent No. 2020303572 was granted to Moleculin and The Board of Regents of The University of Texas System.”
- Oct 20, 2026 · Charter amendment
  “The stockholders of the Company approved an amendment to the Company's amended and restated certificate of incorporation... to effect the reverse stock split... The Amendment was filed with the Secretary of State of the State of Delaware.”
- Oct 16, 2026 · Investor presentation
  “On October 16, 2026, Moleculin Biotech, Inc. (the "Company") is using the attached presentation for its corporate presentation posted on the Company's website and is set forth as Exhibit 99.1 herein.”

## Dividend history and stock splits

Moleculin Biotech, Inc.'s recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-20 · Oct 20, 2026
- 1-for-25 · Dec 1, 2025
- 1-for-15 · Mar 22, 2024

## MBRX short interest

How heavily MBRX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 1.0 |
| Short interest | 54.54K |
| Avg volume | 67.65K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## MBRX news

The latest news and headlines about Moleculin Biotech, Inc. (MBRX).

- [Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting](https://www.globenewswire.com/news-release/2026/11/04/3395620/0/en/moleculin-announces-acceptance-of-annamycin-data-for-presentation-at-the-2026-american-society-of-hematology-ash-annual-meeting.html) · GlobeNewswire Inc. · Nov 4, 2026 · positive sentiment
- [Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine](https://www.globenewswire.com/news-release/2026/09/28/3369741/0/en/moleculin-announces-publication-of-peer-reviewed-cardiac-safety-analysis-of-annamycin-in-frontiers-in-cardiovascular-medicine.html) · GlobeNewswire Inc. · Sep 28, 2026 · positive sentiment
- [Scalable Biotech Manufacturing Unlocks a $14B Market](https://www.benzinga.com/pressreleases/26/03/n51506568/scalable-biotech-manufacturing-unlocks-a-14b-market?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Mar 27, 2026 · positive sentiment
- [Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study](https://www.globenewswire.com/news-release/2026/03/11/3253793/0/en/Moleculin-Releases-Next-CEO-Corner-Segment-Highlighting-MIRACLE-Study.html) · GlobeNewswire Inc. · Mar 11, 2026 · positive sentiment
- [Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain \| DelveInsight](https://www.globenewswire.com/news-release/2025/12/04/3200202/0/en/Acute-Myeloid-Leukemia-Clinical-Trial-Pipeline-Appears-Robust-With-100-Key-Pharma-Companies-Actively-Working-in-the-Domain-DelveInsight.html) · GlobeNewswire Inc. · Dec 4, 2025 · positive sentiment

## About Moleculin Biotech, Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 17 |
| Listed | Jun 2, 2016 |

[Company website](https://www.moleculin.com)

## FAQ

### What is the Moleculin Biotech, Inc. (MBRX) stock price today?

Moleculin Biotech, Inc. (MBRX) is trading at $7.74 (-2.40% on the day) as of 7:56:24 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Moleculin Biotech, Inc.?

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical…

### What is the short interest in MBRX?

As of Oct 30, 2026, MBRX has 54.54K shares short and 1.0 days to cover.

### What exchange is MBRX listed on?

Moleculin Biotech, Inc. (MBRX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time MBRX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=MBRX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Moleculin Biotech, Inc. (MBRX) insider trading](https://massive.com/quote/mbrx/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
